pharma · Metastatic Prostate Cancer · Prostate Cancer · TLX
Telix Innovations
Telix Innovations clinical programs — 8 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Rue de Hermée 255, Herstal, Région wallonne 4040, BE
- Founded
- 2015
- Employees
- 14
- Programs
- 27
- Drugs
- 11
- Patents
- 3
Telix Innovations projects
8 ClinicalTrials.gov programs sponsored by Telix Innovations.
Telix Innovations has 8 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
177Lu-TLX250
Telix Innovations
ccRCC
1 trial -
177Lu-TLX591
Telix Innovations
Metastatic Castration-resistant Prostate Cancer
1 trial -
68Ga-PSMA-11
Telix Innovations
PCA
1 trial -
89Zr-Girentuximab
Telix Innovations
Clear Cell Renal Cell Carcinoma
2 trials -
89Zr-TLX250 PET/CT
Telix Innovations
Clear Cell Renal Cell Carcinoma
1 trial -
Ga-68-PSMA-11
Telix Innovations
Prostate Cancer
1 trial -
Standard of Care
Telix Innovations
Metastatic Prostate Cancer
1 trial -
TLX-101-Tx + Lomustine
Telix Innovations
Neoplastic Disease
1 trial
Frequently asked questions
How many clinical projects does Telix Innovations have?
8 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.